Launched 'Novel Therapy' to develop
a broad-spectrum viral therapeutics.
Established processes for mass production of the scFv.
Proved the permeability of the scFv through
the mucosal layers of small intestine and the lung.
Proved the therapeutic effect of the scFv by
utilizing scFv-expressing intestinal microbiota.
Identified scFv's intrinsic properties
to develop as antiviral therapeutics.
Identified molecular mechanism of action
for the scFv's function on viral diseases.
Established transgenic pigs and chickens expressing the scFv.
Proved the scFv's ability to penetrate into eukaryotic cells.
Established transgenic mice expressing the scFv
to verify scFv's effectiveness as antiviral therapies.
Verified antiviral effectiveness of the selected scFv
against animal viruses. (7 species)
Established transgenic plants - tobacco, lettuce,
potato, rice, and cactus - expressing scFv.
against plant viruses. (7 species)
Isolated scFv with nuclease activities
and identified its tertiary structure.
Started research for the discovery of
a broad-spectrum anti-viral scFv.